FDA OKs Biosimilar Adalimumab for Autoimmune Conditions
November 1st 2018The FDA has approved Sandoz’s biosimilar adalimumab, Hyrimoz (adalimumab-adaz) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.
Read More
2 Commerce Drive
Cranbury, NJ 08512